Answers are grounded in this paper and cite their sources.
Pharmacoresistance remains a major challenge in epilepsy management. The availability of ten new antiepileptic drugs since the late 1980s has not dramatically improved the outcome of refractory epilepsy. This article provides an overview of the contemporary understanding of epilepsy and the limitation of current treatment modalities, discusses putative biological mechanisms of medical intractability and reviews some of the novel strategies under investigation to overcome the challenge of pharmacoresistance.
No takes yet. Share an insight, caveat, or question.
Kwan et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: